このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

TRACON Pharmaceuticals 将来の成長

Future 基準チェック /16

TRACON Pharmaceuticalsの収益は年間121.7%で減少すると予測されていますが、年間利益は年間8.8%で増加すると予想されています。EPS は年間4.7%で増加すると予想されています。

主要情報

8.8%

収益成長率

4.7%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	-121.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Jul 2024

今後の成長に関する最新情報

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

業績と収益の成長予測

OTCPK:TCON - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-1	N/A	-3	1
12/31/2025	N/A	-2	N/A	-6	1
12/31/2024	0	-11	N/A	-15	1
3/31/2024	12	2	6	6	N/A
12/31/2023	12	-4	4	4	N/A
9/30/2023	9	-11	0	0	N/A
6/30/2023	9	-28	-22	-22	N/A
3/31/2023	N/A	-28	-25	-24	N/A
12/31/2022	N/A	-29	-26	-26	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-28	-28	N/A
3/31/2022	0	-33	-25	-24	N/A
12/31/2021	0	-29	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-22	-17	-17	N/A
3/31/2021	N/A	-18	-17	-17	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-16	-18	-18	N/A
6/30/2020	N/A	-18	-20	-20	N/A
3/31/2020	N/A	-19	-22	-22	N/A
12/31/2019	N/A	-23	-24	-24	N/A
9/30/2019	N/A	-26	-28	-28	N/A
6/30/2019	N/A	-30	-27	-27	N/A
3/31/2019	N/A	-34	-32	-32	N/A
12/31/2018	3	-35	-31	-31	N/A
9/30/2018	3	-34	-25	-25	N/A
6/30/2018	10	-24	-17	-17	N/A
3/31/2018	11	-20	-12	-12	N/A
12/31/2017	9	-19	N/A	-13	N/A
9/30/2017	9	-19	N/A	-17	N/A
6/30/2017	3	-26	N/A	-23	N/A
3/31/2017	3	-28	N/A	-28	N/A
12/31/2016	3	-27	N/A	-27	N/A
9/30/2016	4	-32	N/A	-29	N/A
6/30/2016	5	-32	N/A	-27	N/A
3/31/2016	8	-27	N/A	-21	N/A
12/31/2015	8	-24	N/A	-19	N/A
9/30/2015	8	-16	N/A	-15	N/A
6/30/2015	8	-12	N/A	-13	N/A
3/31/2015	4	-10	N/A	-11	N/A
12/31/2014	4	-7	N/A	2	N/A
9/30/2014	3	-7	N/A	3	N/A
6/30/2014	1	-7	N/A	3	N/A
3/31/2014	0	-8	N/A	3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TCONの予測収益成長率 (年間50% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: TCONの収益 ( 8.8% ) US市場 ( 14.7% ) よりも低い成長が予測されています。

高成長収益: TCONの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: TCONの収益は今後 3 年間で減少すると予想されています (年間-121.7% )。

高い収益成長: TCONの収益は今後 3 年間で減少すると予測されています (年間-121.7% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TCONの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

TRACON Pharmaceuticals 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.45 loss

Consensus revenue estimates increase by 50%

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

Recent updates

TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index

Investor sentiment improves as stock rises 16%

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.

TRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Tracon Pharmaceuticals, Inc. Announces Executive Changes

TRACON Pharmaceuticals announces $5M registered direct offering

TRACON Pharma launches $8.8M direct offering

TRACON Pharmaceuticals, Inc. Announces Dosing of First Patient in ENVASARC Pivotal Trial

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study